Role of FLAP and PDE4D in myocardial infarction and stroke: Target discovery and future treatment options

Current Treatment Options in Cardiovascular Medicine

Volumn 8, Issue 3, 2006, Pages 183-192

  Hakonarson, Hakon ^a  

^a DECODE GENETICS   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BLOOD CLOTTING FACTOR 5 LEIDEN; C REACTIVE PROTEIN; CALCIMYCIN; CYSTATHIONINE BETA SYNTHASE; DG 031; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENZYME INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IONOMYCIN; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; MYELOPEROXIDASE; PHOSPHODIESTERASE IV; THROMBOSPONDIN; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; ENZYME INHIBITION; ETHNOLOGY; GENE MAPPING; GENETIC VARIABILITY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LEUKOCYTE ACTIVATION; NONHUMAN; PATHOPHYSIOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

EID: 33646814032     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-006-0011-0     Document Type: Article

References (75)

1. Aboderin I, Kalache A, Ben-Shlomo Y, et al.: Life Course Perspectives on Coronary Heart Disease, Stroke and Diabetes: Key Issues and Implications for Policy and Research. Geneva: World Health Organization; 2002.
2. Bonow RO, Smaha LA, Smith SC Jr, et al.: World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002, 106:1602-1605.
3. Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003, 108:250-252.
4. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
5. Liuzzo G, Biasucci LM, Gallimore JR, et al.: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
7. Chang MK, Binder CJ, Torzewski M, Witztum JL: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002, 99:13043-13048.
8. Verma S, Wang CH, Li SH, et al.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
9. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
10. Ridker PM: Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 2003, 26:III39-III44.
11. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
12. Helgadottir A, Manolescu A, Thorleifsson G, et al.: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004, 36:233-239.
13. Mehrabian M, Allayee H: 5-lipoxygenase and atherosclerosis. Curr Opin Lipidol 2003, 14:447-457.
14. Mehrabian M, Allayee H, Wong J, et al.: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002, 91:120-126.
15. Helgadottir A, Manolescu A, Helgason A, et al.: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006, 38:68-74.
16. Topol EJ: The genomic basis of myocardial infarction. J Am Coll Cardiol 2005, 46:1456-1465.
17. Alberts MI, Tournier-Lasserve E: Update on the genetics of stroke and cerebrovascular disease 2004. Stroke 2005, 36:179-181.
18. Wang Q, Rao S, Shen GQ, et al.: Premature myocardial infarction novel susceptibility locus on chromosome 1p34-36 identified by genome-wide linkage analysis. Am J Hum Genet 2004, 74:262-271.
19. Willett WC: Balancing life-style and genomics research for disease prevention. Science 2002, 296:695-698.
20. Flossmann A, Schulz UG, Rothwell PM: Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004, 35:212-227.
21. Hassan A, Markus HS: Genetics and ischaemic stroke. Brain 2000, 123:1784-1812.
22. Jamrozik K, Broadhurst RJ, Anderson CS, et al.: The role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. Stroke 1994, 25:51-59.
23. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al.: The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003, 35:131-138.
24. Ford-Hutchinson AW: Leukotriene B in inflammation. Crit Rev Immunol 1990, 10:1-12.
25. Dahlen B, Kumlin M, Ihre E, et al.: Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax 1997, 52:342-347.
26. Malik I, Danesh J, Whincup P, et al.: Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001, 358:971-976.
27. Tselepis A, Chapman J: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis 2002, 3:57-68.
28. Hakonarson H, Thorvaldsson S, Helgadottir A, et al.: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005, 293:2245-2256.
29. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.
30. Ridker PM, Hennekens CH, Roitman-Johnson B, et al.: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.
31. Spanbroek R, Grabner R, Lotzer K, et al.: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 2003, 100:1238-1243.
32. Mehrabian M, Allayee H, Wong J, et al.: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002, 91:120-126.
33. Cipollone F, Mezzetti A, Fazia ML, et al.: Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 2005, 25:1665-1670.
34. Bamshad M, Wooding S, Benjamin A, et al.: Deconstructing the relationship between genetics and race. Nat Rev Genet 2004, 5:598-609.
35. Jorde LB, Wooding SP: Genetic variation, classification and 'race'. Nat Genet 2004, 36:S28-S33.
36. Royal CD, Dunston GM: Changing the paradigm from 'race' to human genome variation. Nat Genet 2004, 36:S5-S7.
37. Reiner AP, Ziv E, Lind DL, et al.: Population structure, admixture, and aging-related phenotypes in African American adults: the Cardiovascular Health Study. Am J Hum Genet 2005, 76:463-477.
38. Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG: Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomarkers Prev 2005, 14:1545-1551.
39. Hoggart CJ, Parra EJ, Shriver MD, et al.: Control of confounding of genetic associations in stratified populations. Am J Hum Genet 2003, 72:1492-1504.
40. Aiello RJ, Bourassa PA, Lindsey S, et al.: Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002, 22:443-449.
41. Samuelsson B: Leukotrienes: mediators of immediated hypersensitivity reactions and inflammation. Science 1983, 220:568-575.
42. Nicholls SJ, Hazen SL: Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:1102-1111.
43. Brennan ML, Penn MS, Van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1160.
44. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, et al.: Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet 2002, 70:593-603.
45. Helgadottir A, Gretarsdottir S, St Clair D, et al.: Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005, 76:505-509.
46. Fukumoto S, Koyama H, Hosoi M, et al.: Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ Res 1999, 85:985-991.
47. Houslay MD, Adams DR: PDE4 CAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003, 370:1-18.
48. Palmer D, Tsoi K, Maurice DH: Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res 1998, 82:852-861.
49. Indolfi C, Avvedimento EV, Di Lorenzo E, et al.: Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med 1997, 3:775-779.
50. Indolfi C, Di Lorenzo E, Rapacciuolo A, et al.: 8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J Am Coll Cardiol 2000, 36:288-293.
51. Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
52. Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868-874.
53. Morteza N: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003, 108:1664-1672.
54. Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004, 141:137-147.
55. Casserly IP, Topol EJ: Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and unfolded proteins. Lancet 2004, 363:1139-1146.
56. Gerdes LU, Gerdes C, Kervinen K, et al.: The apolipoprotein e4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. A substudy of the Scandinavian Simvastatin Survival study. Circulation 2000, 101:1366-1371.
57. Kessler C, Spitzer C, Stauske D, et al.: The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 1997, 17:2880-2884.
58. Topol EJ, McCarthy J, Gabriel S, et al.: Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001, 104:2641-2644.
59. McCarthy JJ, Parker A, Moliterno DJ, et al.: Large-scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004, 41:334-341.
60. Stenina OI, Desai S, Kight K, et al.: Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. Circulation 2003, 108:1514-1519.
61. Wessel J, Topol EJ, Ji M, et al.: Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J 2004, 147:905-909.
62. Kato T, Yamada A, Murase Y, et al.: Specific gene polymorphisms could be risk factors for coronary artery disease in individuals with or without hypertension. Circulation 2003, 108(suppl IV):712.
63. Walton B, Willerson JT, Coresh J, Boerwinkle E: Thrombospondin-2 and lymphotoxin: a gene variations predict coronary heart disease in a large prospective study. Circulation 2003, 108(suppl IV):771.
64. Ozaki K, Ohnishi Y, Iida A, et al.: Functional SNPs in the lymphotoxin-gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002, 32:650-654.
65. Ozaki K, Inoue K, Sato H, et al.: Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 2004, 429:72-75.
66. Moster ML: Coagulopathies and arterial stroke. J Neuroophthalmol 2003, 23:63-71.
67. Kahn MJ: Hypercoagulability as a cause of stroke in adults. South Med J 2003, 96:350-353.
68. Kin RJ, Becker RC: Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003, 146:948-957.
69. Carter AM, Catto AJ, Bamford JM, Grant PJ: Gender-specific associations of the fibrinogen beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler Thromb Vasc Biol 1997, 17:589-594.
70. Schmidt H, Schmidt R, Niederkorn K, et al.: Beta-fibrinogen gene polymorphism (C148ÆT) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol 1998, 18:487-492.
71. Carter AM, Catto AJ, Bamford JM, Grant PJ: Platelet GP IIIa P1A and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol 1998, 18:1124-1131.
72. Lee BC, Ahn SY, Doo HK, et al.: Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. Neurosci Lett 2004, 357:33-36.
73. Casas JP, Hingorani AD, Bautista LE, Sharma P: Meta-analysis of genetic studies in ischemic stroke. Arch Neurol 2004, 61:1652-1662.
74. Humphries SE, Morgan L: Genetic risk factors for stroke: insights into pathophysiology from candidate gene approaches. Lancet Neurol 2004, 3:227-235.
75. Rauramaa R, Vaisanen SB, Luong LA, et al.: Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2657-2662.